FDA gives expedited approval to new groundbreaking pancreatic cancer drug

The U.S. Food and Drug Administration granted expedited approval to daraxonrasib, a first‑of‑its‑kind oral medication that blocks a mutated KRAS protein driving tumor growth in more than 90 percent of pancreatic cancers. Sold under the brand name Rasonque by Revolution Medicines, the daily pill more than doubled median overall survival in a pivotal trial, extending life to 13.2 months for patients with metastatic disease whose cancer had become resistant to prior therapies, versus 6.7 months for those receiving standard chemotherapy. The approval came more than six months ahead of the agency’s target timeline, reflecting the urgency of addressing one of the deadliest cancer types in the United States.

The study that underpinned the decision enrolled 500 patients and was funded by Revolution Medicines. Participants were randomly assigned to receive either daraxonrasib or conventional chemotherapy, and the experimental arm not only achieved a striking survival benefit but also reported fewer severe side effects. Pancreatic cancer’s lethality stems largely from its late detection and limited treatment options; the American Cancer Society projects roughly 67,000 new U.S. cases and over 52,000 deaths this year, with a five‑year survival rate of just 13 percent. The drug’s mechanism—using a “molecular glue” to bind multiple KRAS subtypes—overcomes a long‑standing obstacle that rendered KRAS mutations “undruggable,” opening a new therapeutic avenue for a disease that has historically lacked effective targeted agents.

The approval follows heightened public interest after former Senator Ben Sasse described reduced pain while taking the drug on a national television program, prompting the FDA to grant expanded access before formal approval. Acting FDA commissioner Kyle Diamantas emphasized the agency’s duty to accelerate cures, while oncologists expressed optimism that daraxonrasib’s success could catalyze further development of KRAS‑targeted therapies across other cancers, such as lung cancer, where Revolution Medicines is already applying its technology. The breakthrough marks a significant shift in pancreatic cancer treatment and may pave the way for additional innovative drugs in a field long dominated by chemotherapy.

⚡ Effects Interpreter